Medical News

RSS

Purdue Pharma launches Intermezzo for middle-of-the-night insomnia

Purdue Pharma L.P. announced today that Intermezzo (zolpidem tartrate) sublingual tablet CIV is now available in 1.75 mg and 3.5 mg dosage strengths by prescription in retail pharmacies nationwide.

6 Apr 2012

Majority of female kidney failure patients on dialysis may experience sexual problems

The vast majority of female kidney failure patients on dialysis may experience sexual problems, according to a study appearing in an upcoming issue of the Clinical Journal of the American Society Nephrology (CJASN). Additional studies are needed to understand how sexual dysfunction affects dialysis patients' quality of life and psychological wellbeing.

6 Apr 2012

African American women more likely to have ER-negative breast cancer

American women of African ancestry are more likely than European Americans to have estrogen-receptor-negative (ER-negative) breast cancer. There continues to be discussion about the role of low levels of vitamin D in the development of breast cancer for these women.

6 Apr 2012

Sweetheart Ball raises $280,000 to benefit cancer programs and services

The Fifteenth Annual Sweetheart Ball was held on Saturday, February 25, at Eagle Oaks Golf and Country Club in Farmingdale and raised a record breaking $280,000.

6 Apr 2012

FDA clears CooperVision's Avaira Toric contact lenses for astigmatism

CooperVision, Inc. today announced that the U.S. Food and Drug Administration has granted a Special 510(k) clearance for CooperVision's Avaira Toric two-week silicone hydrogel contact lenses for astigmatism.

6 Apr 2012

Collaborative Cross project to develop lab mice with increased genetic diversity

With a 95 percent genomic similarity to humans, mice have long been used to learn about the genetic causes of human disease. Once researchers can shine a light on the genetic factors that cause disease in mice, they can start to develop prevention and treatment options to protect the human population.

6 Apr 2012

Astellas' mirabegron for OAB receives FDA advisory committee approval

Astellas Pharma US, Inc., a U.S. subsidiary of Tokyo-based Astellas Pharma Inc., announced today that the Reproductive Health Drugs Advisory Committee of the U.S. Food and Drug Administration voted that the overall risk/benefit assessment supports approval of mirabegron for the treatment of overactive bladder.

6 Apr 2012

Susan G. Komen Community Health Advisor program kicks off April 12 in Cleveland

More than 110,000 minority and medically underserved women in Northeast Ohio and across the nation will soon have new health resources through a landmark program that trains volunteers to provide breast cancer education and healthcare support in local communities.

6 Apr 2012

Spectrum’s apaziquone Phase 3 trials on bladder cancer do not meet primary endpoint

Spectrum Pharmaceuticals, a biotechnology company with fully integrated commercial and drug development operations with a primary focus in hematology and oncology, today announced that the two double blind, randomized, placebo controlled, Phase 3 clinical trials for apaziquone did not meet their primary endpoint of a statistically significant difference in the rate of tumor recurrence at 2 years between the two arms.

6 Apr 2012

Evergreen Healthcare employs transanal endoscopic microsurgery for colorectal tumor removal

Evergreen Healthcare today announced that it has successfully integrated a colorectal procedure called transanal endoscopic microsurgery to its growing suite of minimally invasive surgical options, reducing the need for major surgery and providing patients with faster recovery times.

6 Apr 2012

Costs for all types of medical plans are expected to increase by 9.9% for 2012

Costs for all types of medical plans are expected to increase by 9.9 percent for 2012, according to a survey by Buck Consultants, A Xerox Company.

6 Apr 2012

SelectHealth announces 2012 Select 25 award recipients

SelectHealth is pleased to announce the recipients of the 2012 Select 25 award. The nonprofit health insurance carrier will give $2,500 to each of the 25 winners to assist them in their efforts to improve health and wellness, or to serve populations with special needs.

6 Apr 2012

Steps to reduce risk of social media sites among teenagers

While social media has made connecting and communicating with anyone at any time as easy as pie, it also has altered teen's social skills and behaviors. Sites such as Facebook, Twitter and MySpace have proven to be great tools to expedite the development of empathy, encourage task-switching or even bring somewhat shy individuals a little more out of their shells. However, social media sites have also fostered a host of psychological and behavioral problems.

6 Apr 2012

TAM protein complex - a potential antibacterial target

Scientists could produce new antibacterial treatments by disarming the molecular pumps bacteria use to bring disease causing molecules in contact with animals and humans.

6 Apr 2012

Amedica to distribute BioDfence DryFlex and Dynamic Bone allograft products

Amedica Corporation, a spinal and reconstructive implant and instrument manufacturer announced today that it will begin distribution of Dynamic Bone, a unique expandable allograft bone provided by Dynamic Surgical Solutions and BioDfence DryFlex, an easy to handle, flexible amniotic membrane manufactured by BioDlogics.

6 Apr 2012

Towards a drug to control cystic fibrosis

Harvard stem cell researchers at Massachusetts General Hospital (MGH) have taken a critical step in making possible the discovery in the relatively near future of a drug to control cystic fibrosis (CF), a fatal lung disease that claims about 500 lives each year, with 1,000 new cases diagnosed annually.

6 Apr 2012

Allscripts Wand now available for EHR users

Allscripts announced the much-anticipated release of Allscripts Wand, which provides users of Allscripts Electronic Health Records a unique, native iPad application that extends the most commonly used functions of Allscripts Professional and Enterprise solutions.

6 Apr 2012

CHL's inflammation biomarkers to be showcased at TEDMED 2012 conference

Cleveland HeartLab Inc. (CHL), a rapidly growing specialty clinical laboratory and cardiovascular disease management company, today announced that its panel of inflammation biomarkers will be featured at next week's TEDMED 2012 conference in Washington.

6 Apr 2012

Key finding in regulation of intraocular pressure in glaucoma

A six-year collaboration between two faculty members of Bascom Palmer Eye Institute of the University of Miami Miller School of Medicine has yielded new insight regarding the regulation of intraocular pressure (IOP) in glaucoma - an irreversible blinding disease that causes progressive visual impairment due to optic nerve damage and is the leading cause of blindness worldwide.

6 Apr 2012

Akebia completes AKB-6548 Phase 2 study for anemia in CKD patients

Akebia Therapeutics, Inc., a pharmaceutical discovery and development company focused on anemia and vascular disorders, today announced that it has successfully completed a randomized, double-blinded, placebo-controlled Phase 2 dose-ranging study of AKB-6548 in patients with stage 3 and 4 chronic kidney disease (CKD).

6 Apr 2012